-- Dr. Brooks Brings Substantial Experience in Leading Oncology
Clinical Development Programs --
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical
oncology company advancing a broad pipeline of novel product candidates
based on its Targeted Protein Therapeutics (TPTs) platform, today
announced the appointment of David Brooks, M.D., Ph.D., to Senior Vice
President, Clinical Development. Dr. Brooks will be responsible for the
execution of Eleven's ongoing and planned clinical trials. He will
report to Arthur DeCillis, M.D., Chief Medical Officer.
"Eleven is at a pivotal inflection point, as we progress our Phase 3
registration trial of Vicinium™ and prepare to advance our second
program, Proxinium™, into a Phase 1/2a study in combination with a
checkpoint inhibitor," said Stephen Hurly, President and Chief Executive
Officer of Eleven Biotherapeutics. "We are pleased to welcome David to
the Eleven team as we continue to build out our clinical development
organization. David brings a highly-relevant skillset, including
experience overseeing the simultaneous development of multiple oncology
programs as monotherapies and in combination with immuno-oncology
agents. We look forward to his contributions as we continue to evaluate
the potential of our locally- and systemically-administered TPTs and
work to bring new medicines that improve upon existing therapeutic
options to patients."
Dr. Brooks joins Eleven Biotherapeutics from Deciphera Pharmaceuticals,
where he served as Vice President, Clinical Research and Translational
Medicine. In this role, Dr. Brooks led the clinical development of four
oncology product candidates, set clinical strategy for assets entering
testing in direct anti-tumor and immune combination therapy, and planned
clinical trials evaluating the combination of immunotherapies with novel
myeloid cell checkpoint blockers. Prior to joining Deciphera, Dr. Brooks
was Senior Director Physician, Oncology Early Clinical Development at
AstraZeneca, where he led the clinical development of a dual specificity
PI3K inhibitor across multiple oncology indications and managed a
portfolio of external alliances and investigator-sponsored studies.
Earlier in his career, Dr. Brooks served as Medical Head, Translational
Medicine at TESARO Inc., as Chief Medical Officer and Senior Vice
President at Generation Health, Inc., and as Medical Director, Global
Clinical Medicine at Abraxis Bioscience, Inc. He also worked at Shire
Human Genetic Therapies, Inc. and Merck & Co., Inc. Dr. Brooks holds a
M.D. and Ph.D. in Molecular Biology from Cornell University. He
completed his residency in Internal Medicine at the University of
Pennsylvania and a fellowship in Medical Genetics at the Children's
Hospital of Philadelphia/Hospital of the University of Pennsylvania. He
also served as an Instructor in Medicine in the Division of Medical
Genetics at the University of Pennsylvania.
"I am pleased to join the Eleven team at such an important time," said
Dr. Brooks. "The Company's lead drug candidates have demonstrated
promising anti-tumor activity and safety as single agents. I am eager to
work with Eleven's team to further demonstrate the potential of Vicinium
in the clinic. I am particularly excited to progress the ongoing Phase 3
registration trial of Vicinium for patients with high-grade non-muscle
invasive bladder cancer, a disease which has not seen meaningful
advancements in approximately forty years."
Dr. Brooks is the third recent addition to Eleven's clinical development
group in recent months. In the first quarter, Eleven appointed Gary
Conboy as Executive Director, Clinical Sciences and Mary Rohrer as
Associate Director, Clinical Operations.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a late-stage clinical oncology company
advancing a broad pipeline of novel product candidates based upon the
Company's TPT platform. The Company's TPTs incorporate a tumor-targeting
antibody fragment and a protein cytotoxic payload into a single protein
molecule in order to achieve focused tumor cell killing. The Company
believes its TPT approach offers significant advantages in treating
cancer over existing ADC technologies. The Company believes its TPTs
provide effective tumor targeting with broader cancer cell-killing
properties than are achievable with small molecule payloads that require
tumor cell proliferation and face multi-drug resistance mechanisms.
Additionally, the Company believes that its TPT's cancer cell-killing
properties promote an anti-tumor immune response that will potentially
combine well with immuno-oncology drugs such as checkpoint inhibitors.
For more information please refer to the Company's website at www.elevenbio.com.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans
and prospects for the Company, the Company's strategy, future
operations, and other statements containing the words "anticipate,"
"believe," "estimate," "expect," "intend," "may," "plan," "predict,"
"project," "target," "potential," "will," "would," "could," "should,"
"continue," and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: the occurrence of any event change or
other circumstances that could give rise to the termination of the
License Agreement, the uncertainties inherent in receiving future
payments pursuant to the License Agreement, the uncertainties inherent
in the initiation and conduct of clinical trials, our ability to
successfully develop our product candidates and complete our planned
clinical programs, our ability to obtain marketing approvals for our
product candidates, expectations regarding our ongoing clinical trials,
availability and timing of data from clinical trials, whether interim
results from a clinical trial will be predictive of the final results of
the trial or results of early clinical studies will be indicative of the
results of future studies, the adequacy of any clinical models,
expectations regarding regulatory approvals, our ability to obtain,
maintain and protect our intellectual property for our technology and
products, availability of funding sufficient for the Company's
foreseeable and unforeseeable operating expenses and capital expenditure
requirements, other matters that could affect the financial performance
of the Company, other matters that could affect the availability or
commercial potential of the Company's product candidates and other
factors discussed in the "Risk Factors" section of the Company's Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports
filed with the Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent the
Company's views as of the date hereof. The Company anticipates that
subsequent events and developments will cause the Company's views to
change. However, while the Company may elect to update these
forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so. These forward-looking
statements should not be relied upon as representing the Company's views
as of any date subsequent to the date hereof.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170517005244/en/
Stern Investor Relations, Inc.
Hannah Deresiewicz, 212-362-1200
Source: Eleven Biotherapeutics, Inc.
News Provided by Acquire Media